| Outcome Measures: |
Primary: Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min), After 10 weeks of treatment | Secondary: Change from baseline in plasma triglyceride, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in plasma cholesterol, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in APO B48, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in free fatty acid levels, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in lipoprotein distribution, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in LDL oxidation, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in postprandial plasma glucose, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in insulin, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in C-peptide, 2 days after the basal test and after 10 weeks of treatment|Change from baseline in low grade inflammation (cytokines and stress oxidative markers), 2 days after the basal test and after 10 weeks of treatment|Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction, 2 days after the basal test and after 10 weeks of treatment
|
